Itron vs Ralliant
ITRI and RAL side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ITRI and RAL compare
Ralliant is the larger company, worth 1.8 times as much as Itron ($7.9B against $4.3B).
Ralliant grew revenue faster over the last twelve months (10.4% versus −3.6% for Itron).
Itron keeps more of each dollar of sales as profit, with a net margin of 12.1% compared with −52.1% at Ralliant.
Ralliant pays a dividend yielding 0.28%; Itron does not pay one.
Itron scores higher on the StockData Score (16 against 7 for Ralliant), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ITRI | RAL |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $7.9B |
| Share price | $98.50 | $71.50 |
| Change, 1 year | −2.4% | 55.7% |
| Change, 5 years | 47.5% | – |
| Beta (5Y) | 1.26 | 0.90 |
| Employees | 5,550 | 7,000 |
| StockData Score | ||
| Total score | 16 (better) | 7 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 15.9× | – |
| P/S | 1.9× (better) | 3.5× |
| P/B | 2.5× (better) | 4.9× |
| EV/EBITDA | 13.1× | – |
| P/FCF | 11.8× (better) | 26.1× |
| FCF yield | 8.5% (better) | 3.8% |
| Fair value | $149.03 | $53.37 |
| Margin of safety | 33.9% (better) | −34.0% |
| Growth | ||
| Revenue growth (TTM) | −3.6% | 10.4% (better) |
| Revenue growth, 5Y average | 1.7% | – |
| Net income growth (TTM) | 8.6% (better) | −607% |
| EPS growth (TTM) | 11.3% (better) | −615% |
| Profitability | ||
| Gross margin | 40.7% | 51.6% (better) |
| Operating margin | 13.7% (better) | −48.3% |
| Net margin | 12.1% (better) | −52.1% |
| FCF margin | 15.8% (better) | 13.3% |
| Return on equity | 16.5% (better) | −51.8% |
| Return on invested capital | 13.4% (better) | −27.8% |
| Financial health | ||
| Debt / equity | 0.93 | 0.71 (better) |
| Net debt / EBITDA | 1.91 | – |
| Interest coverage | 13.8× (better) | −19.0× |
| Current ratio | 2.83 (better) | 1.65 |
| Altman Z-score | 2.32 (better) | 1.51 |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.28% |
| Years of dividend growth | – | 0 |
| Buyback yield | 5.8% | – |
| Shareholder yield | 5.8% (better) | 0.28% |
| Ownership | ||
| Held by institutions | 118% | 102% |
| Held by insiders | 1.6% | 0.51% |
| Insider net buying, 12 months | −$15.1M | −$4.7M (better) |
| Short interest, % of float | 13.8% | 4.3% |
Go deeper
- ITRI stock overview
- ITRI income statement
- ITRI valuation and score
- RAL stock overview
- RAL income statement
- RAL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.